KRAS and non-small cell lung carcinoma: Up to present, the research progress of NSCLC has found many target genes that correlated with tumor metastasis, invasion, prognosis, such as EGFR, KRAS, ALK, ROS1, etc. However, since patients with EGFR, ALK, ROS1 gene mutations currently account for only a portion of patients with non-small cell lung cancer, and some mutations have few drug options, many patients have developed drug resistance after targeted drug therapy, there is an urgent need to discover new potential biomarker for NSCLC (4).